Journal
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
Volume 17, Issue 6, Pages 483-494Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAI.0b013e3181a725eb
Keywords
breast carcinoma; immunohistochemistry; estrogen receptor; progesterone receptors; HER2
Funding
- Fondo de Investigaciones Sanitarias [FIS PI06- 0709]
- Instituto Carlos III RTICCCFIS [RD06/0020/0015]
- Pfizer Laboratories
- Mutua Madrilena Foundation
Ask authors/readers for more resources
The cDNA microarrays allows the classification of breast cancers into 6 groups: luminal A, luminal B, luminal C, normal breast-like, human epidermal growth factor receptor 2-positive, and basal-like. This latter is characterized by the expression of basal cytokeratins (CKs), and frequent negativity for hormone receptors and human epidermal growth factor receptor 2. There is a marked parallelism between triple negative breast carcinomas and basal-like carcinoma, but these are not equivalent terms. Estimated concordance is around 80%. CK5 seems to be the best marker for the identification of these tumors. Other good markers to identify these tumors are CK14, CK17, and epidermal growth factor receptor. A subset of triple negative breast carcinomas has myoepithelial differentiation, with positivities for smooth muscle actin, p63, S-100, and CD10 among others. Recent studies Suggest that basal like carcinomas are originated from mammary stem cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available